Dermira initiated with an Outperform at SVB Leerink

SVB Leerink analyst Pasha Sarraf initiated Dermira with an Outperform rating and $20 price target, stating that the market for primary hyperhidrosis, which Qbrexza serves, is “a largely untapped, but needy market.”

https://thefly.com/landingPageNews.php?id=2868724